Table 3.
Median progression-free survival (PFS) in the first line of treatment depending on the used chemotherapy regimen in patients who received chemotherapy alone or chemotherapy with surgery/radiotherapy.
| Scheme | n (%) | Median PFS (95% CI) [Months] | HR (95% CI) | p |
|---|---|---|---|---|
| Patients treated with chemotherapy alone (n = 82) | ||||
| ADIC | 37 (45.1%) | 3.6 (2.1–5.0) | 1 | |
| HD-IFO | 25 (30.5%) | 2.7 (1.3–4.1) | 1.6 (0.95–2.70) | 0.079 |
| EI | 13 (15.9%) | 3.1 (1.1–5.1) | 0.91 (0.48–1.72) | 0.763 |
| AI | 2 (2.4%) | 1.9 (NR-NR) | 0.27 (0.04–2.00) | 0.199 |
| AP3 | 5 (6.1%) | 5.9 (5.6–6.3) | 0.76 (0.30–1.95) | 0.565 |
| Patients treated with chemotherapy and surgery/radiotherapy (n = 33) | ||||
| ADIC | 10 (30.3%) | 8.6 (7.7–9.4) | 1 | |
| HD-IFO | 15 (45.5%) | 6.5 (1.7–11.3) | 1.31 (0.56–3.04) | 0.534 |
| EI | 4 (12.1%) | 7.5 (0.0–15.7) | 1.36 (0.41–4.50) | 0.616 |
| AI | 4 (12.1%) | 12.1 (5.5–18.6) | 0.48 (0.10–2.26) | 0.353 |
ADIC, doxorubicin + dacarbazine; AI, doxorubicin + ifosfamide; AP3, doxorubicin + cisplatin; EI, etoposide + ifosfamide; HD-IFO, high-dose ifosfamide.